A phase 3, randomized, open-label, multicenter study evaluating the efficacy and safety of TAR-210 erdafitinib intravesical delivery system versus investigator’s choice of intravesical chemotherapy in participants with high-risk non-muscle-invasive bladder cancer with susceptible FGFR alterations who had received intravesical Bacillus Calmette-Guérin (BCG)

Authors
Category Primary study
Registry of TrialsISRCTN registry
Year 2025
This article has no abstract
Epistemonikos ID: 7f07eddb16d3634d9d9fe8d8356d5a5ec8eff8a5
First added on: Sep 11, 2025